Do Black Men with Metastatic Castration-Resistant Prostate Cancer Have Worse Outcomes Than White Patients? A Nationwide VA Study

Abstract

Black men have a higher prostate cancer (PC) risk and mortality than white men. Whether these differences are due to lack of access to care or more aggressive biology is debated. However, a few small studies suggested black men may actually have better outcomes than white men when treated with metastatic castration-resistant PC (mCRPC) drugs. We hypothesize that black men with mCRPC will have similar responses to modern mCRPC therapies but worse compliance; after accounting for poorer compliance, black men will actually have better responses to these therapies than white men. Our objective is, to create a true nation-wide cohort from the Veterans Affairs (VA) Health System. Our preliminary analyses identified 46,535 men treated with one of 6 drugs for mCRPC (Cabazitaxel, Docetaxel, Abiraterone, Enzalutamide, Radium-223,and Sipuleucel-T). We will 1. Determine drug efficacy among black and white men with mCRPC;2. Determine drug compliance among black and white men with mCRPC; and 3. Determine drug efficacy among black and white men with mCRPC after accounting for compliance.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 2020
Accession Number
AD1121017

Entities

People

  • Adriana Vidal

Organizations

  • Cedars-Sinai Medical Center

Tags

DTIC Thesaurus Topics

  • African Americans
  • Biomedical Research
  • California
  • Data Analysis
  • Data Science
  • Drug Therapy
  • Education
  • Electronic Mail
  • Genetics
  • Health Care
  • Health Services
  • Information Science
  • Institutional Review Board
  • Machine Learning
  • Medical Personnel
  • Neoplasms
  • Oncology
  • Prostate Cancer
  • Radiation Oncology
  • Radiotherapy
  • Statistical Analysis
  • Therapy

Fields of Study

  • Medicine
  • Psychology

Readers

  • Gender and Food Studies
  • Oncology
  • Prostate Cancer Biology.